Drugs / IMC-S118AI
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | — | type 1 diabetes mellitus | — | “The Company filed a clinical trial application (CTA) for IMC-S118AI (PPI x PD1) in December 2025” immunocore.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07493122 | Apr 2026 → Nov 2030 expected | type 1 diabetes mellitus | Immunocore Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-S118AI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493122 ↗ |
| Route | Other | “IMC-S118AI solution for infusion/injection” NCT07493122 ↗ |